Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Premaitha pushing on in spite of Illumina prenatal testing patent lawsuit

This article was originally published in Clinica

Executive Summary

UK noninvasive prenatal testing specialist Premaitha Health has been dealt a blow after larger rival Illumina sued it for patent infringement. But while Premaitha CEO Stephen Little described the development as a “nuisance,” he is confident that the firm’s technology does not infringe any third-party IP, he told Clinica.

You may also be interested in...



Yourgene Offers Premaitha An Asian Reprieve From Illumina Patent Tussle

Noninvasive prenatal testing specialist Premaitha Health has agreed to acquire Taiwan's Yourgene Bioscience, enabling the UK company to expand its presence in Asia. The deal also offers an important market that has not been tainted by ongoing patent litigation between Premaitha and US next-generation sequencing firm Illumina.

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel